Atlas
Back to Pharma Services
Target·Pharma Services

UCB

Brussels, Belgiumucb.com1expert edge

Global biopharmaceutical company founded 1928, specializing in neurological and autoimmune therapies; completed $1.9B acquisition of Zogenix in March 2022 to strengthen rare disease position.

Why interesting to a deal team

Expert advised on $1.9B rare disease/neurology acquisition; demonstrates pharma M&A expertise in strategic bolt-on acquisitions.

Experts connected to this company

ES

Eric Stewart

Senior Managing Director, European M&A

Leerink Partners

Fund GPLondon

Stewart built Leerink's European healthcare M&A practice from scratch, bringing a decade of Lazard deal relationships spanning Mallinckrodt, Abcam/Danaher and Galderma.

Sources